Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models.

Killion EA, Wang J, Yie J, Shi SD, Bates D, Min X, Komorowski R, Hager T, Deng L, Atangan L, Lu SC, Kurzeja RJM, Sivits G, Lin J, Chen Q, Wang Z, Thibault SA, Abbott CM, Meng T, Clavette B, Murawsky CM, Foltz IN, Rottman JB, Hale C, Véniant MM, Lloyd DJ.

Sci Transl Med. 2018 Dec 19;10(472). pii: eaat3392. doi: 10.1126/scitranslmed.aat3392.

PMID:
30567927
2.

Molecular basis for the loss-of-function effects of the Alzheimer's disease-associated R47H variant of the immune receptor TREM2.

Sudom A, Talreja S, Danao J, Bragg E, Kegel R, Min X, Richardson J, Zhang Z, Sharkov N, Marcora E, Thibault S, Bradley J, Wood S, Lim AC, Chen H, Wang S, Foltz IN, Sambashivan S, Wang Z.

J Biol Chem. 2018 Aug 10;293(32):12634-12646. doi: 10.1074/jbc.RA118.002352. Epub 2018 May 24.

3.

TREM2-activating antibodies abrogate the negative pleiotropic effects of the Alzheimer's disease variant Trem2R47H on murine myeloid cell function.

Cheng Q, Danao J, Talreja S, Wen P, Yin J, Sun N, Li CM, Chui D, Tran D, Koirala S, Chen H, Foltz IN, Wang S, Sambashivan S.

J Biol Chem. 2018 Aug 10;293(32):12620-12633. doi: 10.1074/jbc.RA118.001848. Epub 2018 Mar 29.

4.

Impact of antibody subclass and disulfide isoform differences on the biological activity of CD200R and βklotho agonist antibodies.

Grujic O, Stevens J, Chou RY, Weiszmann JV, Sekirov L, Thomson C, Badh A, Grauer S, Chan B, Graham K, Manchulenko K, Dillon TM, Li Y, Foltz IN.

Biochem Biophys Res Commun. 2017 May 13;486(4):985-991. doi: 10.1016/j.bbrc.2017.03.145. Epub 2017 Mar 28.

PMID:
28363871
5.

Discovery and bio-optimization of human antibody therapeutics using the XenoMouse® transgenic mouse platform.

Foltz IN, Gunasekaran K, King CT.

Immunol Rev. 2016 Mar;270(1):51-64. doi: 10.1111/imr.12409. Review.

PMID:
26864104
6.

Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.

Stewart R, Morrow M, Hammond SA, Mulgrew K, Marcus D, Poon E, Watkins A, Mullins S, Chodorge M, Andrews J, Bannister D, Dick E, Crawford N, Parmentier J, Alimzhanov M, Babcook JS, Foltz IN, Buchanan A, Bedian V, Wilkinson RW, McCourt M.

Cancer Immunol Res. 2015 Sep;3(9):1052-62. doi: 10.1158/2326-6066.CIR-14-0191. Epub 2015 May 5.

7.

AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma.

Hamblett KJ, Kozlosky CJ, Siu S, Chang WS, Liu H, Foltz IN, Trueblood ES, Meininger D, Arora T, Twomey B, Vonderfecht SL, Chen Q, Hill JS, Fanslow WC.

Mol Cancer Ther. 2015 Jul;14(7):1614-24. doi: 10.1158/1535-7163.MCT-14-1078. Epub 2015 Apr 30.

8.

A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism.

Liu Z, Leng EC, Gunasekaran K, Pentony M, Shen M, Howard M, Stoops J, Manchulenko K, Razinkov V, Liu H, Fanslow W, Hu Z, Sun N, Hasegawa H, Clark R, Foltz IN, Yan W.

J Biol Chem. 2015 Mar 20;290(12):7535-62. doi: 10.1074/jbc.M114.620260. Epub 2015 Jan 12.

9.

Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity.

Graves JD, Kordich JJ, Huang TH, Piasecki J, Bush TL, Sullivan T, Foltz IN, Chang W, Douangpanya H, Dang T, O'Neill JW, Mallari R, Zhao X, Branstetter DG, Rossi JM, Long AM, Huang X, Holland PM.

Cancer Cell. 2014 Aug 11;26(2):177-89. doi: 10.1016/j.ccr.2014.04.028. Epub 2014 Jul 17.

10.

Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know.

Foltz IN, Karow M, Wasserman SM.

Circulation. 2013 Jun 4;127(22):2222-30. doi: 10.1161/CIRCULATIONAHA.113.002033. Review. No abstract available.

PMID:
23733968
11.

Pharmacology of AMG 181, a human anti-α4 β7 antibody that specifically alters trafficking of gut-homing T cells.

Pan WJ, Hsu H, Rees WA, Lear SP, Lee F, Foltz IN, Rathanaswami P, Manchulenko K, Chan BM, Zhang M, Xia XZ, Patel SK, Prince PJ, Doherty DR, Sheckler CM, Reynhardt KO, Krill CD, Harder BJ, Wisler JA, Brandvig JL, Lynch JL, Anderson AA, Wienkers LC, Borie DC.

Br J Pharmacol. 2013 May;169(1):51-68. doi: 10.1111/bph.12134.

12.

Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex.

Foltz IN, Hu S, King C, Wu X, Yang C, Wang W, Weiszmann J, Stevens J, Chen JS, Nuanmanee N, Gupte J, Komorowski R, Sekirov L, Hager T, Arora T, Ge H, Baribault H, Wang F, Sheng J, Karow M, Wang M, Luo Y, McKeehan W, Wang Z, Véniant MM, Li Y.

Sci Transl Med. 2012 Nov 28;4(162):162ra153. doi: 10.1126/scitranslmed.3004690.

13.

A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo.

Eberlein C, Kendrew J, McDaid K, Alfred A, Kang JS, Jacobs VN, Ross SJ, Rooney C, Smith NR, Rinkenberger J, Cao A, Churchman A, Marshall JF, Weir HM, Bedian V, Blakey DC, Foltz IN, Barry ST.

Oncogene. 2013 Sep 12;32(37):4406-16. doi: 10.1038/onc.2012.460. Epub 2012 Oct 29.

PMID:
23108397
14.

MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo.

Jenkins DW, Ross S, Veldman-Jones M, Foltz IN, Clavette BC, Manchulenko K, Eberlein C, Kendrew J, Petteruti P, Cho S, Damschroder M, Peng L, Baker D, Smith NR, Weir HM, Blakey DC, Bedian V, Barry ST.

Mol Cancer Ther. 2012 Aug;11(8):1650-60. doi: 10.1158/1535-7163.MCT-11-1027. Epub 2012 Jun 7.

15.

Kinetic analysis of unpurified native antigens available in very low quantities and concentrations.

Rathanaswami P, Richmond K, Manchulenko K, Foltz IN.

Anal Biochem. 2011 Jul 1;414(1):7-13. doi: 10.1016/j.ab.2011.02.034. Epub 2011 Mar 1.

PMID:
21371417
16.

Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG.

Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, Ng SB, Born T, Retter M, Manchulenko K, Sweet H, Foltz IN, Wittekind M, Yan W.

J Biol Chem. 2010 Jun 18;285(25):19637-46. doi: 10.1074/jbc.M110.117382. Epub 2010 Apr 16.

17.

Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types.

Kaplan-Lefko PJ, Graves JD, Zoog SJ, Pan Y, Wall J, Branstetter DG, Moriguchi J, Coxon A, Huard JN, Xu R, Peach ML, Juan G, Kaufman S, Chen Q, Bianchi A, Kordich JJ, Ma M, Foltz IN, Gliniak BC.

Cancer Biol Ther. 2010 Apr 15;9(8):618-31. Epub 2010 Apr 20.

PMID:
20150762
22.

Supplemental Content

Loading ...
Support Center